Danish Real-World Study Compares Empagliflozin and GLP-1RAs for Cardiovascular Outcomes in T2D
A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes
Abstract
A Danish medical records study aims to compare empagliflozin and GLP-1RAs on serious cardiovascular outcomes in type 2 diabetes patients.